超级碰在线-超级碰碰永久免费视频播放-超级碰碰碰免费视频播放-超级碰碰碰免费视频-亚洲国产99在线精品一区69堂-亚洲高清资源在线观看

美國Aerpio   
Aerpio Therapeutics公司宣布其作為一個獨立的臨床階段生物技術公司而開張，開發治療多種疾病的新型小分子Tie-2激動劑和HIF-1a穩定劑。
Aerpio公司是從Akebia Therapeutics公司中剝離出來的

Aerpio Therapeutics is a new, clinical-stage biotechnology company focused on the development of novel small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Aerpio was created in a spin-out transaction from Akebia Therapeutics to enable more rapid development of its exciting compounds. It is managed by the same successful team from Akebia, employing a similar outsourced approach to pharmaceutical development.

Aerpio's two lead programs include a Tie-2 activator for diabetic macular edema (DME) and vascular leak, and a Hypoxia-inducible Factor 1-α (HIF1-α) stabilizer for wound healing and the treatment of inflammatory bowel disease. The lead compound for the Tie-2 program, AKB-9778, is currently completing its initial Phase 1 clinical trial, and the HIF1-α stabilization program is progressing toward the clinic with support, in part, from the United States Department of Defense and National Institutes of Health.

The Aerpio team is composed of highly experienced individuals from all facets of pharmaceutical development. During the last 4 years, this team has successfully sharpened their skills at Akebia Therapeutics in the fast paced world of venture backed biopharmaceuticals.